Volume 4, Issue 4 , Pages 266-274, October 2011
Differential effects of deep TMS of the prefrontal cortex on apathy and depression
Background
Apathy is one hallmark of major depression (MDD). It is distinguished by lack of emotion, whereas other aspects of depression involve considerable emotional distress. Investigating both apathy and depression may increase the degree of treatment efficacy for both ailments together and apart.
Objective
Evaluate the differential effects of deep transcranial magnetic stimulation (DTMS) over the prefrontal cortex (PFC) on apathy and other aspects of depression in patients suffering from a depressive episode.
Methods
Fifty-four treatment-resistant MDD patients were evaluated with the Hamilton Rating Scale for Depression (HRSD), and then treated with DTMS. Apathy-related items from HRSD (ApHRSD) were compared with the remaining items from HRSD (DepHRSD). Antidepressant medications were withdrawn and active DTMS treatment was administered at 20 Hz, 5 days a week for 4 weeks. Changes in HRSD were recorded. Primary efficacy time point was 1 week after the end of active treatment.
Results
At screening, ApHRSD distribution was unimodal (moderate apathy), with low correlation (r = 0.17) between ApHRSD and DepHRSD. After treatment, a third had remitted apathy, and the correlation between ApHRSD and DepHRSD had dramatically increased (r = 0.83). Severe ApHRSD (≥ 7) at screening correlated with nonremission for both ApHRSD (R2 = 0.1993, P = .0012) and DepHRSD (R2 = 0.0860, P = .0334).
Conclusions
DTMS over the PFC improved both apathy and depression similarly. However, DTMS did not lead to MDD remission if ApHRSD at screening was ≥ 7 of 12. Further investigation using a larger sample will determine whether screening apathy at baseline could be used to predict efficacy of DTMS in MDD patients.
Keywords: MDD, treatment-resistant, DTMS, H-coil, ApHRSD, DSM-V
To access this article, please choose from the options below
This study was supported by the Rosenzweig-Coopersmith Fund and Brainsway Inc.
Drs. Levkovitz and Zangen are consultants for and have financial interests in Brainsway Inc., which has commercial interests in the development of deep TMS coils. Dr. Isserles receives financial support from Brainsway Inc.
Yechiel Levkovitz and Aharon Sheer contributed equally to this work.
PII: S1935-861X(10)00206-8
doi:10.1016/j.brs.2010.12.004
© 2011 Elsevier Inc. All rights reserved.
Volume 4, Issue 4 , Pages 266-274, October 2011
